Is INmune Bio, Inc. (INMB) a Buy, Sell, or Hold?
INmune Bio, Inc.
NASDAQ:INMB
$2.02 USD
$0.16 (8.6%)
- Volume
- 1.05M
- Average Volume
- 707.02K
- Market Capitalization
- $53.7M
- P/E Ratio
- -1.20
- Dividend Yield
- 0.00%
- Price Target
- $22.00
- Year High
- $3.24
- Year Low
- $1.09
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $4.24
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | David J. Moss |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | INMB |
| CUSIP | 45782T105 |
| CIK | 0001711754 |
| Web | https://www.inmunebio.com |
| Phone | 858 964 3720 |
| Currency | USD |
| Employees | 21 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.08 |
| Payout Ratio | 0.00 |
| Current Ratio | 4.24 |
| Quick Ratio | 4.24 |
| Cash Ratio | 3.96 |
Sales & Book Value
| Annual Sales | $50000 |
| Price / Sales | 0.00 |
| Cash Flow | -0.78 |
| Price / Cash Flow | -2.58 |
| Price / Book | 2.74 |
Price Target and Rating
| Average Stock Price Forecast | $22.00 |
| High Stock Price Forecast | $22.00 |
| Low Stock Price Forecast | $22.00 |
| Forecast Upside/Downside | -90.82% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 9 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-1.86 |
| Trailing P/E Ratio | -1.20 |
| PEG Ratio | -1.35 |
| P/E Growth | -1.35 |
| Net Income | $-45.93M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -170.86% |
| Return on Assets | -161.13% |
Financials Score
| AltmanZ Score | -9.25 |
| Piotroski Score | 2.00 |
| Working Capital | 17.43M |
| Total Assets | 25.82M |
| Ebit | -25.2M |
| Market Cap | 49.45M |
| Total Liabilities | 6.19M |
Poll Results
About INmune Bio, Inc. (NASDAQ:INMB) Stock
INmune Bio, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies. Its primary objective is to harness the body's innate immune system to combat various illnesses. The company is actively engaged in developing and bringing to market therapeutic candidates designed to address a spectrum of conditions such as blood cancers, solid tumors, and chronic inflammatory diseases. Its pipeline features key development programs including: INKmune: Aimed at treating women suffering from relapsed or refractory ovarian carcinoma and individuals diagnosed with high-risk myelodysplastic syndrome. INB03: An immunotherapy targeting patients with both hematologic malignancies and solid tumors. XPro1595: Under development for the treatment of Alzheimer's disease. INmune Bio ... holds licensing agreements with entities including Xencor, Inc., Immune Ventures, LLC, the University of Pittsburgh, and University College London. Established in 2015, INmune Bio is headquartered in Boca Raton, Florida.
INmune Bio to Present Positive Phase 2 Imaging Data for XPro in Early Alzheimer's Disease at AAIC
2026-07-09 07:00:00
Advanced MRI analyses showed early treatment-related changes in white matter myelin integrity and cortical microstructure at Week 24, supporting biologic activity of selective soluble TNF inhibition.
2026-07-01 07:00:00
Secures Global Framework for Composition-of-Matter and Method-of-Treatment Claims Covering Lead Program Ebstrocel for Epidermolysis Bullosa and Next-Generation Engineered Modalities Extending to 2045 BOCA RATON, Fla. , July 01, 2026 (GLOBE NEWSWIRE) -- -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a late-stage biotechnology company focused on inflammation and immunology, today announced that it has submitted its CORDStrom platform patent application into the U.
2026-07-01 07:00:00
Secures Global Framework for Composition-of-Matter and Method-of-Treatment Claims Covering Lead Program Ebstrocel for Epidermolysis Bullosa and Next-Generation Engineered Modalities Extending to 2045
INmune Bio Inc. Achieves MHRA Approval of PIP for CORDStrom™
2026-06-25 07:00:00
Approval of pediatric strategy validates clinical data package and accelerates the regulatory path for CORDStrom™ in the United Kingdom
2026-06-23 08:00:00
MHRA minutes from May 12 pre-MAA Scientific Advice meeting confirm agreement across all questions covering CMC, non-clinical and clinical evidence packages MHRA pediatric feedback recognizes MissionEB Phase 2 data as demonstrating clinically meaningful symptomatic benefit, particularity pain and pruritis, and states the data could support positioning as chronic or intermittent supportive therapy for RDEB BOCA RATON, Fla, June 23, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced that it has received official, accepted meeting minutes from its recent face-to-face pre-Marketing Authorization Application (pre-MAA) Scientific Advice meeting with the UK Medicines & Healthcare products Regulatory Agency (MHRA) for CORDStrom™ (Ebstrocel™) in Recessive Dystrophic Epidermolysis Bullosa (RDEB). The May 12, 2026, meeting resulted in written alignment across all questions submitted by the Company and provides a clear regulatory path for INmune Bio's planned 2026 UK Marketing Authorization Application (MAA) seeking Conditional Marketing Authorization for Ebstrocel™ in RDEB.
2026-06-02 08:00:00
XPro1595 showed a highly significant treatment effect in the full mITT population (p=0. 0028; d=0. 46; n=200), demonstrating broad tissue-level target engagement and treatment-related biological effect. Efficacy was further strengthened in biomarker-enriched patients with elevated levels of inflammation (p=0.
2026-06-02 08:00:00
XPro1595 showed a highly significant treatment effect in the full mITT population (p=0.0028; d=0.46; n=200), demonstrating broad tissue-level target engagement and treatment-related biological effect.
INmune Bio Publishes Phase 2 MINDFuL Trial Results in NPJ Dementia, Advancing the XPro™ Platform
2026-05-15 08:00:00
Boca Raton, FL, May 15, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB), a clinical-stage biotechnology company developing therapies that target innate immune dysfunction, today announced that results from its Phase 2 MINDFuL trial in Alzheimer's disease have been published in the peer-reviewed journal NPJ Dementia. The study evaluated the safety, biomarker engagement, and clinical efficacy of XPro™ (XPro1595, pegipanermin) in patients with mild Alzheimer's disease characterized by biomarkers of inflammation. In a pre-specified analysis of the protocol-defined Alzheimer's Disease with inflammation (ADi) subgroup, XPro™ showed directionally consistent benefit across cognitive, global, functional, behavioral, and biomarker endpoints over 24 weeks, with no amyloid-related imaging abnormalities (ARIA) observed.
Frequently Asked Questions
-
What is the current INmune Bio, Inc. (INMB) stock price?
-
INmune Bio, Inc.(NASDAQ:INMB) stock price is $2.02 in the last trading session. During the trading session, INMB stock reached the peak price of $3.244 while $1.09 was the lowest point it dropped to. The percentage change in INMB stock occurred in the recent session was 8.6% while the dollar amount for the price change in INMB stock was $0.16.
-
INMB's industry and sector of operation?
-
The NASDAQ listed INMB is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of INMB?
-
Joshua S. Schoonover | General Counsel
Cory Randall Ellspermann | Interim Chief Financial Officer
Daniel Frederick Carlson | Head of Investor Relations
Mark William Lowdell | Chief Scientific Officer & Chief Manufacturing Officer
David J. Moss | President, Chief Executive Officer, Treasurer, Secretary & Director -
How many employees does INMB have?
-
Number of INMB employees currently stands at 21. INMB operates from 225 NE Mizner Boulevard, Boca Raton, FL 33432, US.
-
Link for INMB official website?
-
Official Website of INMB is: https://www.inmunebio.com
-
How do I contact INMB?
-
INMB could be contacted at phone #858 964 3720 and can also be accessed through its website. INMB operates from 225 NE Mizner Boulevard, Boca Raton, FL 33432, US.
-
How many shares of INMB are traded daily?
-
The average number of INMB shares traded daily for last 3 months was 707.02K.
-
What is the market cap of INMB currently?
-
The market value of INMB currently stands at $53.7M with its latest stock price at $2.02